Polfa Warszawa S.A.
ul. Karolkowa 22/24
01-207 Warsaw
REGON: 000043937
NIP: 525-000-04-81
KRS: 0000147193
District Court for the City of Warsaw in Warsaw,
XII Commercial Division of the National Court Register
Initial capital: 230 000 000 zł
Paid-in capital: 230 000 000 zł
Telephone exchange
tel. 22 691 39 00/ 519 903 900
fax 22 691 38 27/ 519 903 827
e-mail: polfa@polfawarszawa.pl
Informations for shareholders
tel. 22 691 39 02
e-mail: akcje@polfawarszawa.pl
Management Office
tel. 22 691 38 24
fax 22 691 38 21
e-mail: m.mazurek@polfawarszawa.pl
Management Board
tel. 22 691 38 25
tel. 22 691 38 26
e-mail: sekretariat@polfawarszawa.pl
e-mail: sekretariat2@polfawarszawa.pl
Finance Department
tel. 22 691 38 26
e-mail: sekretariat2@polfawarszawa.pl
HR Department
tel. 22 691 38 71
e-mail: d.bialek@polfawarszawa.pl
tel. 22 691 38 82
e-mail: j.gocman@polfawarszawa.pl
Research and Development Department
tel. 22 535 70 33
fax 22 823 30 26
e-mail: OBRbiuro@polfawarszawa.pl
Logistics Department
tel. 22 691 36 17
e-mail: j.ignaciuk@polfawarszawa.pl
Production Department
tel. 22 691 37 42
e-mail: sekretariat2@polfawarszawa.pl
Technical Department
tel. 22 691 38 26
e-mail: sekretariat2@polfawarszawa.pl
e-mail: e.witecka@polfawarszawa.pl
Quality Department
tel. 22 691 31 47/ 885 505 622
e-mail: tomasz.klisowski@polpharma.com
tel. 22 691 38 51/ 512 102 493
e-mail: i.salasinska@polfawarszawa.pl
Drug Registration
tel. 22 691 35 65
fax 22 691 35 64
e-mail: r.szwed@polfawarszawa.pl
Complaints
tel. 22 691 35 82/ 665 619 251
tel. 22 691 39 17/ 510 992 128
fax. 22 691 35 50
e-mail: reklamacje@polfawarszawa.pl
Medical Information
Medical Information is provided by Zakłady Farmaceutyczne Polpharma S.A.:
phone 22 364 61 00, extension 2
fax 22 364 61 66
Contact form: https://polpharma.pl/en/about-us/contact/
Media contact
tel. 58 563 80 52
e-mail: rzecznik@polpharma.com
Polpharma Group
We are the largest Polish manufacturer of pharmaceuticals and a leader of the…
read moreNew investment
Lorem ipsum dolor sit amet, consectetur adipisicing elit, sed do eiusmod tempor…
read more